PUBLISHER: The Business Research Company | PRODUCT CODE: 1826894
PUBLISHER: The Business Research Company | PRODUCT CODE: 1826894
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It occurs when the immune system attacks the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination difficulties.
The primary treatment options for CIDP include intravenous immunoglobulin (IVIg), corticosteroids, plasmapheresis, physiotherapy, and other supportive therapies. IVIg is a blood-derived product containing antibodies that help regulate the immune system and treat autoimmune, immune deficiency, and inflammatory conditions. These treatments are administered through various routes, including intravenous, oral, and others. Diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Treatments are distributed through hospitals, pharmacies, online pharmacies, and specialty clinics, with key end users including hospitals, research institutions, and homecare settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The chronic inflammatory demyelinating polyneuropathy (CIDP) market research report is one of a series of new reports from The Business Research Company that provides chronic inflammatory demyelinating polyneuropathy (CIDP) market statistics, including the chronic inflammatory demyelinating polyneuropathy (CIDP) industry global market size, regional shares, competitors with the chronic inflammatory demyelinating polyneuropathy (CIDP) market share, detailed chronic inflammatory demyelinating polyneuropathy (CIDP) market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (CIDP) industry. This chronic inflammatory demyelinating polyneuropathy (CIDP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic inflammatory demyelinating polyneuropathy (cidp) market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to an increasing geriatric population, improvement in treatment options, increased awareness and early diagnosis, advances in immunology and autoimmune research, and rising prevalence of autoimmune diseases.
The chronic inflammatory demyelinating polyneuropathy (cidp) market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, patient advocacy and awareness campaigns, and improved healthcare infrastructure. Major trends in the forecast period include increasing prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, growing research and development activities, emergence of biosimilar therapies, and development of personalized medicine approaches.
The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. neurology by increasing costs for intravenous immunoglobulin (IVIG) therapies and nerve conduction study equipment imported from Austria and Japan, potentially worsening disability outcomes and raising neuromuscular specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing healthcare expenditure is expected to drive the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. The rise in healthcare spending is fueled by investments in medical infrastructure, increased demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare access. As healthcare expenditure grows, it enhances access to cutting-edge treatments, early diagnosis, and better management of CIDP, all of which contribute to improved patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a notable acceleration compared to the 0.9% growth seen in 2022. This growing healthcare expenditure is thus propelling the CIDP market.
Leading companies in the CIDP market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, enhance patient outcomes, and offer more targeted immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, with an initial dose followed by maintenance doses to manage long-term disease and improve neuromuscular function.
In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for CIDP in China. This partnership aims to provide a convenient, effective, and well-tolerated treatment, addressing unmet medical needs and improving patient outcomes. Argenx SE, a Netherlands-based biotechnology company, focuses on advancing therapies for severe autoimmune diseases, including CIDP.
Major players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., and AdvaCare Pharma.
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chronic inflammatory demyelinating polyneuropathy (cidp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chronic inflammatory demyelinating polyneuropathy (cidp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic inflammatory demyelinating polyneuropathy (cidp) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
- 2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
- 3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
- 4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
- 5) By End User: Hospitals; Research Institutions; Homecare Settings
- Subsegments:
- 1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
- 2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
- 3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
- 4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
- 5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Sanofi SA; Novartis AG; Takeda Pharmaceutical Company Limited; Baxter International Inc.; CSL Behring (CSL Limited); Grifols S.A.; Sun Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Octapharma AG; Cipla Inc.; Hikma Pharmaceuticals plc; Halozyme Therapeutics; Hualan Biological Engineering Inc; argenx SE; Hovione; Nihon Pharmaceutical Co. Ltd.; Bio Products Laboratory Ltd.; AdvaCare Pharma.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Characteristics
3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends And Strategies
4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate Analysis
- 5.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Addressable Market (TAM)
6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation
- 6.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous Immunoglobulin
- Corticosteroids
- Plasmapheresis
- Physiotherapy
- Other Treatments
- 6.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous
- Oral
- Other Route of Administration
- 6.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Electrodiagnostic Testing
- Nerve Conduction
- Electromyography (EMG)
- Spinal Fluid Analysis
- Other Diagnosis
- 6.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Pharmacies
- Online Pharmacies
- Specialty Clinics
- 6.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Research Institutions
- Homecare Settings
- 6.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Corticosteroids
- Intravenous Corticosteroids
- 6.7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Plasmapheresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single-Exchange Plasmapheresis
- Multiple-Exchange Plasmapheresis
- 6.8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Physiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Muscle Strengthening Exercises
- Balance And Coordination Therapy
- 6.9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunosuppressive Agents
- Monoclonal Antibodies
7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional And Country Analysis
- 7.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 8.1. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 9.1. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 9.2. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 10.1. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 11.1. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 11.2. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 12.1. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 13.1. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 14.1. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 14.2. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 15.1. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 15.2. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 16.1. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 17.1. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 18.1. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 19.1. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 20.1. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 21.1. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 21.2. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 22.1. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 23.1. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 23.2. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 24.1. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 24.2. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 25.1. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 25.2. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 26.1. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 26.2. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 27.1. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 28.1. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 28.2. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
- 29.1. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 29.2. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape And Company Profiles
- 30.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape
- 30.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
31. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Other Major And Innovative Companies
- 31.1. Baxter International Inc.
- 31.2. CSL Behring (CSL Limited)
- 31.3. Grifols S.A.
- 31.4. Sun Pharmaceutical Industries Ltd.
- 31.5. Mitsubishi Tanabe Pharma Corporation
- 31.6. Octapharma AG
- 31.7. Cipla Inc.
- 31.8. Hikma Pharmaceuticals plc
- 31.9. Halozyme Therapeutics
- 31.10. Hualan Biological Engineering Inc
- 31.11. argenx SE
- 31.12. Hovione
- 31.13. Nihon Pharmaceutical Co. Ltd.
- 31.14. Bio Products Laboratory Ltd.
- 31.15. AdvaCare Pharma
32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
34. Recent Developments In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
35. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market High Potential Countries, Segments and Strategies
- 35.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
